Skip to content
Homepage
Author:
VANDA PHARMACEUTICALS INC
Posted Date:
July 29, 2026
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
VANDA PHARMACEUTICALS INC
July 29, 2026
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis – A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
VANDA PHARMACEUTICALS INC
July 16, 2026
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
VANDA PHARMACEUTICALS INC
July 15, 2026
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
VANDA PHARMACEUTICALS INC
July 10, 2026
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
VANDA PHARMACEUTICALS INC
July 7, 2026
